Guillaume Canaud (MD, PhD)
@CanaudLab
Followers
2K
Following
2K
Media
66
Statuses
679
Translational medicine. Hôpital Necker Enfants Malades/Université Paris Cité.
Paris, France
Joined June 2018
Aujourd’hui nous célébrions les 10 ans d’introduction de l’alpelisib (BYL719) chez Emmanuel, le premier patient PIK3CA traité dans le monde. Immense fierté🇫🇷 10 years on alpelisib for Emmanuel, the first ever PROS patient treated. Fantastic accomplishment for all of us 🎉🥳🍾🥂
0
4
29
Our latest article just released. Congratulations to @IlariaGalasso and @morin_gbrl 🍾🍾🎉🎊Vascular malformations: from genetics to therapeutics | EMBO Molecular Medicine
link.springer.com
EMBO Molecular Medicine - Vascular malformations (VMs) are congenital disorders characterized by structurally abnormal blood and lymphatic vessels. Advances in genetics have revealed that most...
0
0
7
Our latest review on kidney drug repositioning in @Kidney_Int. Congrats to the 2 outstanding contributors @morin_gbrl and @IsnardPierre1👏🍾🥂Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease
kidney-international.org
Phosphoinositide 3-kinase α (PI3Kα) is a ubiquitous lipid kinase that transduces extracellular growth, proliferation, and metabolism signals. Genes involved in the PI3Kα signaling pathway are...
0
2
3
#France2030 | Félicitations à Guillaume Canaud @CanaudLab, lauréat d’une Chaire d’excellence en Biologie/Santé pour son projet sur les malformations vasculaires liées à KRAS. 🎯Objectif : développer des thérapies ciblées pour une médecine ultra personnalisée. 👏🏼
📢#France2030 15 nouveaux chercheurs et chercheuses d'exception récompensés pour les « Chaires d’excellence en Biologie / Santé » !🧑🔬 Ce dispositif vise à renforcer l’attractivité de la recherche biomédicale française🧪🇫🇷🥼 Pour découvrir les lauréats👉 https://t.co/YM1NEh6WS7
0
1
6
Excellente nouvelle et merci pour votre soutien! Ce financement devrait accélérer l’identification de nouveaux traitements pour les malformations vasculaires secondaires a des mutations de KRAS 🍾🎊🥳 Wonderful news! This is a great funding for KRAS-vascular malformations! 🙏🙏
📢#France2030 15 nouveaux chercheurs et chercheuses d'exception récompensés pour les « Chaires d’excellence en Biologie / Santé » !🧑🔬 Ce dispositif vise à renforcer l’attractivité de la recherche biomédicale française🧪🇫🇷🥼 Pour découvrir les lauréats👉 https://t.co/YM1NEh6WS7
2
2
25
Here is our latest publication. Somatic PIK3R1 mutations in patients and treatment with alpelisib. Congratulations to the whole team and particularly to two very talented students @morin_gbrl and @Alexandre Garneau🥳🥂🍾 EMBO Molecular Medicine
link.springer.com
EMBO Molecular Medicine - Mutations in PIK3R1 have recently been identified in patients with overgrowth syndromes and complex vascular malformations. PIK3R1 encodes p85α which acts as the...
3
5
31
Key messages: 1-No fertility issues in 3 PROS patients with prolonged exposure to alpelisib 2-No embryotoxicity 3-Unfortunately, we observed disease recurrence following alpelisib withdrawal 4-But, no resistance to drug when alpelisib was reintroduced after pregnancies.
0
2
10
Happy to share our latest article: « First report of successful pregnancies after treatment with alpelisib for PIK3CA-related overgrowth spectrum » Congratulations to the whole team and particularly to @morin_gbrl 🥳🍾🎉 @ejhg_journal
https://t.co/7e2SKxBgT8 Key messages 👇
2
6
21
Our latest paper is out today in @PNAS. Congratulations to Quitterie, Sophia, Marina, and the entire team!🍾🤩🥳PIK3CA gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effect | PNAS
pnas.org
PIK3CA-related disorders are rare genetic disorders due to somatic gain-of-function mutations in PIK3CA during embryonic development, a pathway inv...
1
5
18
Our latest paper is out today in @PNAS. Congratulations to Quitterie, Sophia, Marina, and the entire team!🍾🤩🥳PIK3CA gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effect | PNAS
pnas.org
PIK3CA-related disorders are rare genetic disorders due to somatic gain-of-function mutations in PIK3CA during embryonic development, a pathway inv...
1
5
18
[PUBLICATION] First report of successful pregnancies after treatment with alpelisib for PIK3CA-related overgrowth spectrum. ➡️Fertility preserved ➡️No embryotoxicity ➡️Disease remained responsive after treatment pause 📖Details here: https://t.co/o49nzEF5DK
0
6
6
Key messages: 1-No fertility issues in 3 PROS patients with prolonged exposure to alpelisib 2-No embryotoxicity 3-Unfortunately, we observed disease recurrence following alpelisib withdrawal 4-But, no resistance to drug when alpelisib was reintroduced after pregnancies.
0
2
10
Happy to share our latest article: « First report of successful pregnancies after treatment with alpelisib for PIK3CA-related overgrowth spectrum » Congratulations to the whole team and particularly to @morin_gbrl 🥳🍾🎉 @ejhg_journal
https://t.co/7e2SKxBgT8 Key messages 👇
2
6
21
Here is our latest publication. Somatic PIK3R1 mutations in patients and treatment with alpelisib. Congratulations to the whole team and particularly to two very talented students @morin_gbrl and @Alexandre Garneau🥳🥂🍾 EMBO Molecular Medicine
link.springer.com
EMBO Molecular Medicine - Mutations in PIK3R1 have recently been identified in patients with overgrowth syndromes and complex vascular malformations. PIK3R1 encodes p85α which acts as the...
3
5
31
Thank you so much Fouad! It was great to meet you. Congratulations, you gave an outstanding lecture on PKD See you in Houston
An absolutely sensational and inspirational story of how a brilliant physician-scientist advocated for his patient and led to full FDA approval of alpelisib in PROS! Dr @CanaudLab what an honor to meet you! See you in @ASNKidney kidney week
0
1
7
Merci Monsieur le ministre. Ce fut un honneur de le piloter avec le Professeur Linglart. Nous remercions les 300 personnes qui ont activement participé à son écriture. J’espère que ce plan ambitieux permettra d’améliorer le quotidien des patients atteints de maladies rares.
Ce matin, nous avons lancé le Quatrième Plan Nationale Maladies Rares (PNMR4) Avec @CaVautrin , @yannickneuder et @FerracciMarc , nous continuons à renforcer l’engagement du pays pour accompagner les plus de 3 millions de personnes touchées par les 7000 pathologies concernées
0
3
19
Merci 😊
Guillaume Canaud reçoit le Prix Innovation. Il récompense ses travaux sur le repositionnement d’une molécule pour traiter le syndrome de Cloves, une maladie rare très sévère. La 🏅 est remise par Bruno Bonnell, Secrétaire général à l'investissement. https://t.co/bdamM0Ma1L
2
0
13
Merci 😊
🗓 mardi 10 décembre : Prix Inserm 2024 ✨ 📢 Les équipes d’Inserm Transfert étaient présentes pour cette soirée qui a mis à l'honneur la recherche scientifique de l'Inserm. 🏆 Nous adressons nos félicitations au Professeur Guillaume Canaud @CanaudLab pour son Prix Innovation !
1
0
11